Chronic Allograft Nephropathy Clinical Trial
— RSCS-CampathOfficial title:
Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients
After Campath induction, followed with kidney transplantation, patients will be randomly
assigned to receive either tacrolimus or cyclosporine microemulsion in combination with
mycophenolates. Patients will be followed including protocol biopsy at 1, 12, 36, 60 month
posttransplant, regular nuclein acid testing (NAT) for cytomegalovirus (CMV), Epstein-Barr
virus (EBV) and BK virus (BKV) in urine and blood.
The investigation is undertaken to clarify the reason for equal survival rates for patients
on cyclosporine and tacrolimus despite the lower rejection rate on tacrolimus.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | September 2014 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 60 Years |
Eligibility |
Inclusion Criteria: - recipient of kidney allograft - previous Campath induction Exclusion Criteria: - CNI intolerance |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Russian Federation | National Research Centre of Surgery | Moscow |
Lead Sponsor | Collaborator |
---|---|
Russian Academy of Medical Sciences | Russian Scientific Center of Surgery |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | patient survival | 10 years | Yes | |
Primary | Graft survival | 10 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00999258 -
Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01265615 -
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT00541814 -
Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function
|
Phase 4 | |
Not yet recruiting |
NCT00659620 -
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy
|
Phase 1/Phase 2 | |
Completed |
NCT01056835 -
Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
|
Phase 3 | |
Completed |
NCT05682313 -
Validity of Strain Elastography for the Evaluation of Chronic Allograft Nephropathy
|
N/A | |
Completed |
NCT00975000 -
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
|
Phase 3 | |
Terminated |
NCT00568477 -
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
|
Phase 2 | |
Completed |
NCT00007787 -
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
|
N/A | |
Completed |
NCT00005010 -
Prevention of Kidney Transplant Rejection
|
Phase 3 |